ATLAS fair value
$19.32
Above fair value · 110% premium
Teva Pharmaceutical Industries stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · NYSE
Prices as of Oct 26, 2026 · USD
$19.32
Above fair value · 110% premium
51%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS estimates Teva Pharmaceutical Industries's fair value at about $19.32 per share (reasonable range: $14.54 to $35.75). At $40.49, the stock trades 110% above it.
It is calculated with a blend of a discounted cash-flow model and peer valuation multiples. Confidence in the estimate is medium. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Teva Pharmaceutical Industries a 51% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $38.49 and $42.76; in 9 out of 10, between $35.06 and $46.94. Estimated annual volatility is 26%.
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Teva Pharmaceutical Industries sits above fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks TEVA has traded between $19.23 and $42.02. Today it is 3.7% below that high and 111% above its low.
On the business: revenue grew 4.3% year over year; net margin is 8.2%; it trades at 65.4 times earnings.
Its beta is 0.80: it tends to move less than the market.
Teva Pharmaceutical Industries Ltd. ADR is a global pharmaceutical company focused on the development, production, and sale of medicines.
Want to see everything about Teva Pharmaceutical Industries?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
About $19.32 per share according to ATLAS (reasonable range: $14.54 to $35.75). With the stock at $40.49, it is 110% above it.
51%: close to a coin flip. In half of the simulated outcomes, TEVA ends the month between $38.49 and $42.76.
Teva Pharmaceutical Industries's market capitalization is $46.2B. Its price-to-earnings (P/E) ratio is 65.4: you pay $65.4 for each $1 of yearly earnings.
ATLAS estimates annual volatility at 26%. In a typical month, half of the outcomes end between $38.49 and $42.76.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy